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ABSTRACT
Background. The frigate His Norwegian Majesty’s ship (HNoMS) Fridtjof Nansen was participa-
ting in operations in the Gulf of Aden in support of the EU mission tasked with protecting vessels
from the threat of piracy. The crew was therefore prioritized and given the first batch of Influenza
A (H1N1) vaccine (Pandemrix®).
O bject ives . To investigate the type, frequency, and intensity of side effects after whole-crew
vaccination with Pandemrix vaccine in healthy subjects in a controlled environment.
Material and methods. A hundred and thirty-three members of the crew were vaccinated, and
then they participated in the study. The side effects of the vaccination were evaluated through
a survey.
Results. Seventy-five per cent of the vaccinated sailors reported adverse reactions to the vac-
cine, with 9% not being able to perform their daily duties for one day. Muscle pain, headaches,
malaise, and fatigue were the most frequent symptoms reported.
Conclusions. The vaccination program using Pandemrix H1N1 vaccine resulted in a high rate of
side effects, which were generally mild and resolved within a few days. No serious lasting side
effects of the vaccination were reported or registered. The adverse effects of the vaccination did
not affect the operational capacity of the vessel.
(Int Marit Health 2010; 61; 4: 246–250)
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INTRODUCTION
Immunization is still the method of choice in pre-
ventive medicine in order to combat epidemic di-
seases [1]. As a result of the World Health Organiza-
tion declaring a ”public health emergency of inter-
national concern” on 25 April 2009, after the
outbreak in Mexico of pandemic influenza A (H1N1)
virus, the Norwegian health authorities initiated a po-
pulation-wide vaccination strategy using the Pande-
mrix® H1N1 vaccine. This was in line with several
other countries which implemented their plans for
responding to pandemic influenza. The vaccination
of the Norwegian population started in September
2009 and vulnerable groups were prioritized. The
groups targeted initially were pregnant women, in-
digenous populations, and persons with gross obesi-
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ty or serious underlying medical conditions. Togeth-
er with caregivers of small children and subjects
between the ages of six months and 24 years, these
groups had been identified worldwide as the most
vulnerable to poor outcomes [2, 3].
The transmission of contagious diseases like in-
fluenza is of concern to the shipping industry since
it could affect the safe operation of vessels. In addi-
tion to safety hazards, a non-operative crew would
have financial consequences as well as the practical
consequence of having to re-crew the ship. Recent-
ly, a vessel from a major shipping company had to be
re-crewed due to food poisoning, which was very ta-
xing for the manning organization and had a consi-
derable financial cost. It could also be argued that
contamination of a ship’s crew could be more exten-
sive due to increased contact between personnel on
board as a result of confined working and living con-
ditions. Thus, empirical studies on whole-crew vacci-
nation are called for.
Studies have shown that adverse responses to
influenza vaccine vary. For instance, a study of Tur-
kish health workers reported that as many as 36% of
the vaccinated sample showed at least one side ef-
fect [5]. There was no relationship between adverse
responses and age and gender. However, health
workers vaccinated for the first time reported higher
levels of side effects than groups who had been vac-
cinated before. Reasons for opposition to vaccina-
tion were the idea that influenza could not be con-
sidered a serious illness (29.5%), the vaccine’s low
level of credibility (no immunization; 26%), lack of
reward for participating in the vaccination study
(25%), fear of side effects (10.7%), a preference for
other preventive actions (17.9%), and fear of injec-
tions/needles (6.9%).
Since vaccination is the primary prevention stra-
tegy in combating pandemic diseases, more studies
on side effects are called for because of the general
public debate about vaccination and the variation in
attitudes to vaccination found in vaccination studies.
The present study was designed to investigate the
frequency and type of adverse responses to H1N1
vaccine during whole-crew vaccination. In spite of
reports of serious side effects of “swine-flu” vaccine
(H5N1), such as Guillain-Barré syndrome [6], these
effects are not common. The most frequently repor-
ted adverse responses to the H1N1 vaccine are mild
reactions at the injection site and systemic reactions
[6–10]. In addition, researchers have evaluated the
occurrence of selected adverse events, including
neurologic, immune system, or other serious reac-
tions. According to these studies, none of the en-
rolled participants experienced these selected events
[ref. in 8, 9]. One study reported tenderness, pain,
redness, and hardening of skin, swelling, and brui-
sing [8] as common local side effects. The reactions
were reported to be generally mild or moderate and
resolved after 72 hours. The most common systemic
side effects were muscle aches. In addition, whole-
body side effects occurred in response to H1N1 va-
ccination. Headaches, malaise (feeling out-of-sorts),
muscle pain, chills, nausea, vomiting, and fever are
examples [8]. In a study of immunogenicity after vac-
cination of two different doses of H1N1 vaccine,
Greenberg et al. [9] reported 56.3% local adverse
effects after receiving the vaccine. The most frequent
local side effects were injection site tenderness and
pain. Of the subjects, 53.8% reported systemic ad-
verse effects. The most frequently reported symptoms
were headaches, malaise, and myalgia. The symp-
toms were mild for both the local and systemic symp-
toms (86.3%). Greenberg et al. [9] also reported unso-
licited adverse effects in 45% of the subjects, 9.2% of
which were evaluated as being related to vaccina-
tion. The majority of symptoms (64.7%) were repor-
ted as mild. Unsolicited symptoms encompassed
headaches, oropharyngeal pain and back pain. Clark
et al. [10] reported higher levels of local side effects
(e.g. pain at injection site: 70%) within a period of
seven days of vaccination and 42% showing the sys-
temic adverse response of muscle aches.
Most studies on adverse effects of vaccination
have used the general population as subjects. These
samples could be biased by the lack of control of
the subjects participating in the studies. This includes
pre-morbidity and co-morbidity, exposure (types and
level), as well as other contextual factors such as
temperature and nutrition.
One way to study the prevalence of side effects
in more controlled environments is by utilizing naval
personnel on sea duty. Naval personnel are selected
both somatically and psychologically. One can there-
by reduce the influence of co-morbidity that could
affect the reporting of adverse effects of vaccination.
Another advantage of using naval personnel at sea
is the control this gives over contextual variables.
Since sea-going personnel operate in an isolated
environment, they are exposed to the same sources
of contamination and nutrition, etc. This results in
increased control of third variables that can influ-
ence the reporting of adverse effects of vaccination.
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The Frigate HNoMS Fridtjof Nansen participated
in an international anti-piracy operation in the Gulf
of Aden as part of Operation Atalanta. As a standard
procedure, personnel in international operations were
prioritized in the vaccination procedure in order to
maintain military operational capability.
The aim of the present study was to investigate
the type, frequency, and intensity of side effects af-
ter vaccination with Pandemrix® (H1N1) vaccine in
healthy subjects in a controlled environment. This
was motivated by a need for knowledge about vacci-
nation programs involving the whole crew of a vessel




The frigate was manned by a crew of 149 sailors.
Seven sailors did not wish to participate in the vacci-
nation program and an additional five subjects had
previously shown influenza-like symptoms (either ver-
ified or suspected H1N1). Four subjects were not
vaccinated due to lack of vaccine. Thus, 133 (89%)
of the crew were vaccinated and participated in the
study. Intensity data for six sailors were lost due to
technical problems. The crew was screened medi-
cally and psychologically in accordance with the
Armed Forces’ procedure before embarking on in-
ternational operations.
QUESTIONNAIRE
A 13-item (incl. an item reporting no side ef-
fects) self-report questionnaire was developed in
which the intensity (light, moderate, or severe) of
ordinary side effects of influenza vaccine was re-
gistered. The items included headaches, malaise,
muscle pain, swelling of the injection site, pain in
joints, fatigue, sleep loss, skin abnormalities, and
fever. In addition, the questionnaire included one
item asking whether the symptoms resulted in sail-
ors not being able to perform their scheduled du-
ties as well as the length of absence from duty.
The questionnaire also included an open-ended
item in which other unspecified symptoms could
be reported. The subjects could report multiple
symptoms when filling in the questionnaire.
PROCEDURE
The vaccination program was carried out in week
45 of 2009 after the crew returned from Norway
from a two-week leave/maintenance period. The vac-
cination program was conducted over a four-day
period in order to prevent any reduction in the ope-
rational capability of the crew as a result of side ef-
fects. The vaccine was administered intramuscular-
ly in the deltoid muscle of the non-dominant hand.
The questionnaire was administered to all personnel
at the same time and collected three days after the
administration of the last vaccine. The vessel was
sailing during the whole vaccination and observa-
tion period, and was thus isolated from outside influ-
ence.
RESULTS
The response rate to the questionnaire was 100%.
Of the subjects, 33 (25%) did not report any adverse
reactions to the vaccine, while 100 (75%) reported
various side effects. Twelve (9%) subjects reported
the symptoms to be so severe that they were not
able to perform their normal duties. Eleven of these
subjects were absent from watch duty for one day,
and one was absent for two days. Although 12 sub-
jects were unable to perform their normal duties, the
side effects causing this absence were not consi-
dered to be severe by the medical staff on board the
vessel. Possible long-term effects were monitored by
the surgeons, anaesthesiologists and nurses who
made up the on-board medical team. No long-term
effects were observed by the medical team through-
out the operation.
Table 1 shows subjective evaluation (frequencies
and percentages) of intensity of the side effects dur-
ing the first three days after vaccination.
DISCUSSION
No severe side effects were reported as a re-
sult of the vaccination program using Pandemrix®
vaccine, and the side effects reported did not in-
fluence the operation of the ship. This is in line
with other reports on the side effects of “swine
flu” vaccine. [8] However, a higher than expected
rate of side effects was found. A total of 75% of
those vaccinated reported adverse responses af-
ter vaccination. This is higher than other reports
[4]. In an Australian study, approximately 44% of
participants reported mild side effects within se-
ven days of receiving the first dose of flu vaccine.
Researchers tested an inactivated H1N1 vaccine
developed by CSL Ltd. on a group of 240 volun-
teers [ref in 8]. However, the present study shows
a lower rate of side effects compared to the 86%
of subjects who reported adverse reactions after
one or two doses of the Novartis H1N1 vaccine.
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The most frequent symptom of the Novartis vac-
cine was the local side effect of injection site pain;
the reactions were generally mild or moderate and
resolved after 72 hours [ref. in 8]. Contrary to
Greenberg et al. [9] and Clark [10], the present
study also showed higher frequencies of systemic
side effects compared to local effects. The type of
vaccine used in the present study could have
caused our high numbers of side effects. An al-
ternative interpretation could be the high response
rate in the present study, which could have re-
sulted in higher levels of recorded symptoms. The
response rate in this study is also considerably
higher than that observed following the nation-
wide vaccination program in which 2.2 million
(45%) members of the Norwegian population par-
ticipated [11]. This compliance rate could be due
to military personnel’s perception of the operatio-
nal consequences of a widespread influenza out-
break on board. Another interpretation could be
the sailors’ positive attitude to recommendations
from authorities.
Eleven per cent of the crew did not report for
duty due to adverse effects of the vaccine. This did
not affect the ship’s organization or operation. The
barrier to taking “sick-leave” while on a mission and
leaving your work to your fellow sailors is very high.
Some of those who were absent from duty for a day
reported that, if they had been on land, the sick leave
would have lasted four to five days. However, this
proportion of a crew on sick leave after whole-crew
vaccination could have a greater effect on a civilian
vessel due to lower manning levels on board com-
mercial vessels.
The most frequently reported symptom in the
present study was muscle pain. This is a common
minor side effect. Eleven per cent of the sailors re-
ported severe muscle pain caused by the vaccina-
tion. The present study also found high frequen-
cies of the systemic side effects of headaches, fa-
tigue, and malaise. Forty-one per cent of the subjects
reported one or more of these three symptoms; 24%
of them reported the symptoms to be mild, 17 to
19% reported moderate symptoms, and 7% repor-
ted severe symptoms. Systemic effects were also re-
ported by CSL and recipients of Novartis vaccine
referred to in a 2009 review by Doyle [8]. Approxi-
mately 36% of volunteers who were given the swine
flu vaccine manufactured by CSL experienced mild
systemic side effects. Eight per cent of vaccine re-
cipients reported moderate systemic side effects,
and less than 1% experienced a severe adverse
reaction to immunization. Severe intensity was re-
ported for side effects such as malaise, muscle pain,
and nausea. The present study revealed higher fre-
quencies of moderate and severe symptom intensi-
ty (moderate = 17–19%; severe = 7%). Muscle aches
were the most common systemic side effect repor-
ted by participants receiving the H1N1 vaccine pro-
duced by Novartis, and no severe systemic side ef-
fects were reported. Thus, our study is in line with
previously reported data on systemic adverse res-
Table 1. Frequencies (n) and percentages (%) for subjective evaluations of reported side effects during the first three days
after vaccination. The table is broken down by intensity level
Side effect M i l d Moderate Severe Tota l
n % n % n % n %
Muscle pain 3 0 24 4 4 3 5 1 4 1 1 8 8 7 0
Headaches 17 1 3 24 1 9 9 7 5 0 3 9
Fatigue 1 9 1 5 2 2 17 9 7 5 0 3 9
Malaise 1 8 1 4 2 2 17 9 7 4 9 3 8
Pain in joints 1 5 1 2 1 0 8 8 6 3 3 2 6
Swelling of the 9 7 3 2 0 0 1 2 9
injection site
Fever 1 1 9 5 4 6 5 2 2 1 8
Sleep-loss 9 7 3 2 6 5 1 8 1 4
Skin abnormalities 3 2 0 0 1 1 4 3
Nightmare* 1 0.7
*Reported as other symptoms
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ponses to H1N1 vaccines. However, due to the small
sample size, the prevalence and type of symptoms
should be interpreted with some caution.
Self-reported data have methodological limitations.
The data are based on subjective evaluation of symp-
toms, which could result in a bias in reporting, or
they could be the result of other transmittable sour-
ces of the reported effects. However, during the ob-
servation period, the medical team was present on
24-hours standby. Thus, medical evaluations were
possible, and no outbreak of contagious diseases was
present during the observation period that could
explain the reported level of symptoms.
CONCLUSIONS
The vaccination program using the Pandemrix®
H1N1 vaccine resulted in a high rate of side effects,
which were generally mild and resolved within a few
days. Nine per cent of the vaccinated subjects showed
a severity of symptoms that led to the subjects being
absent from their regular duties. This did not affect the
operation of the vessel. A system of whole-crew vacci-
nation over a four-day period is one possible way of
reducing the operational consequences of possible side
effects when administering the vaccine. The decision
to vaccinate the whole crew was based on recommen-
dations from the Joint Medical Staff, based on the pan-
demic threat level and the need to vaccinate a high
percentage of the population in order to minimize the
risk of illness through the virus spreading via sick and
contaminated personnel. No severe long-term adverse
effects of the vaccine were found on HNoMS Fridtjof
Nansen’s operations in the Gulf of Aden.
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